Continuous infusion of piperacillin/tazobactam in patients with severe infections: A possible pharmacokinetic optimisation?

Ann Pharm Fr. 2014 May;72(3):146-51. doi: 10.1016/j.pharma.2013.12.006. Epub 2014 Jan 20.

Abstract

Piperacillin/Tazobactam is a time-dependent antimicrobial combination (beta-lactam/beta-lactamase inhibitor) commonly used in the treatment of severe Gram-negative infections. The optimisation of its time-dependent bactericidal activity via continuous infusion could improve clinical outcomes. Several studies have been realized on the relevance of a continuous infusion, but, to date, no definitive position can be adopted on the matter and a well-designed randomized controlled trial is warranted. In other articles, continuous infusion regimens are also more cost efficient. This article is an update, including the most recent trials about this subject.

Keywords: Beta-lactam; Bêta-lactamine; Infusion; Perfusion; Pharmacocinétique; Pharmacokinetics; Piperacillin; Pipéracilline; Tazobactam.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / administration & dosage*
  • Anti-Bacterial Agents / economics
  • Anti-Bacterial Agents / pharmacokinetics*
  • Anti-Bacterial Agents / therapeutic use
  • Bacterial Infections / drug therapy*
  • Drug Costs
  • Drug Stability
  • Humans
  • Infusions, Intravenous
  • Penicillanic Acid / administration & dosage
  • Penicillanic Acid / analogs & derivatives*
  • Penicillanic Acid / economics
  • Penicillanic Acid / pharmacokinetics
  • Penicillanic Acid / therapeutic use
  • Piperacillin / administration & dosage
  • Piperacillin / economics
  • Piperacillin / pharmacokinetics
  • Piperacillin / therapeutic use
  • Piperacillin, Tazobactam Drug Combination
  • beta-Lactamase Inhibitors

Substances

  • Anti-Bacterial Agents
  • beta-Lactamase Inhibitors
  • Piperacillin, Tazobactam Drug Combination
  • Penicillanic Acid
  • Piperacillin